Thirty years of cyclophosphamide: Assessing the evidence

Lupus

Volumn 16, Issue 3, 2007, Pages 212-216

  Houssiau, Frédéric ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cyclophosphamide; Lupus nephritis; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID;

ALOPECIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; EARLY MENOPAUSE; ETHNIC GROUP; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GONADAL DISEASE; HEALTH CARE ORGANIZATION; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HUMAN; INFECTION; KIDNEY FAILURE; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDICAL CARE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; PREMATURE GONADAL FAILURE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RACE DIFFERENCE; REMISSION; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU;

CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; RHEUMATOLOGY;

EID: 33947731195     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203306075613     Document Type: Conference Paper

References (20)

1. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003; 82: 299-308.
2. Austin III HA, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
3. Boumpas DT, Austin III HA, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
4. Illei GG, Austin III HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
5. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis, the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
6. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
7. Houssiau FA, Vasconcelos C, D'Cruz D et al. Early response to immunosuppressive therapy predicts good renal oucome in lupus nephritis. Lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004; 50: 3934-3940.
8. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
9. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003; 12: 692-696.
10. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-2568.
11. Donadio JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151-1155.
12. Gourley MF, Austin III HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
13. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC. Treatment of diffuse profilerative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
14. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188-1195.
15. Ognenovski VM, Marder W, Somers EC et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004; 31: 1763-1767.
16. Houssiau FA, Vasconcelos C, D'Cruz D et al. Long-term outcome of patients randomized in the Euro-Lupus Nephritis Trial: further evidence that a low-dose IV cyclophosphamide induction regimen achieves good results. Ann Rheum Dis 2006; 65 (Suppl II): 64.
17. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
18. Chan TM, Tse K-C, Tang CS et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
19. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-2228.
20. Steinberg AD. Reply to a Letter to the Editor. Arthritis Rheum 1992; 35: 605.